Another way to improve the care is by increasing knowledge of our patients with hematologic malignancies of their disease; this might be achieved by patient's organizations. If patients don't have the right information, they won't try to access the right treatment. Therefore, it is essential ...
Lastly, acquired resistance to BTKis is important to consider because of worse clinical outcomes such as decreased OS and PFS in this patient population.30Acquired ibrutinib resistance can occur in up to 38% of patients and most commonly develops through aC481Sresidue mutation, which prevents irre...